Key Financial Figures for the Nine-Month Period 2026

Key Financial Figures for the Nine-Month Period 2026

Key Financial Results for the Nine-Month Period 2026 12.5% Increase in Adjusted EBITDA from continuing operations

Peania, November 19, 2026 – Lavipharm S.A. informs the investment community of its key consolidated financial results for the nine-month period of 2026.

The Group’s adjusted earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) from continuing operations for the first nine months of 2026 increased by 12.5%, amounting to €10.71 million compared to €9.52 million during the corresponding period of the previous year. Adjusted EBITDA from continuing and discontinued operations amounted to €10.71 million, compared to €10.47 million, posting an increase of 2.3%. It is noted that the previous year’s EBITDA included a gain of €0.94 million from the sale of the pharmacy network.

Announcement